Danish enzyme manufacturer Novozymes sees profits rise  

Denmark's Novozymes has published its 2004 financial result which shows a 8% rise in net profits from DKK 726 mn to DKK 782 mn

Danish enzyme manufacturer Novozymes has published its 2004 financial result in a stock exchange announcement which shows a 8% rise in net profit from DKK 726 mn (USD 131 mn) to DKK 782 (USD 141 mn). The result was better than forecast in January 2004, and in line with the adjusted sum announced in September. Operating profits were up by 11%, from DKK 982 mn (USD 177 mn) to 1.09 bn (USD 196 mn).


Novozymes expects to continue its upward advance in 2005. Net profits are forecast to rise by 5%, and operating profits just under 6%. Steen Risgaard, group chief executive of Novozymes says that if the low US dollar exchange rate continues at its current level, the market situation will increasingly be affected, and thus the company's key numbers. The news is reported by national newspaper Berlingske Tidende and on Novozymes' website.


Novozymes is a world leader in enzymes and microbiotech. Headquartered in Bagsværd on the outskirts of Copenhagen, it employs 3,900 people in 30 countries. Novozymes produces and sells more than 600 products in 130 countries. The company's B shares are listed on Copenhagen Stock Exchange.


Link > Novozymes 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×